Zoetis Inc. Files 8-K on Director Changes and Compensation

Ticker: ZTS · Form: 8-K · Filed: 2024-05-23T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

TL;DR

Zoetis filed an 8-K detailing director changes and executive comp. Watch for governance shifts.

AI Summary

Zoetis Inc. filed an 8-K on May 21, 2024, reporting on several key corporate events. These include the departure of a director, the election of new directors, and updates to executive compensatory arrangements. The filing also addresses amendments to the company's articles of incorporation or bylaws and the submission of matters to a vote of security holders.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing is routine corporate housekeeping and does not indicate any immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

Who departed from Zoetis Inc.'s board of directors?

The filing indicates the departure of a director, but the specific name is not provided in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 21, 2024.

What are the main items covered in this 8-K filing?

The filing covers the departure of directors, election of directors, compensatory arrangements of certain officers, amendments to articles of incorporation or bylaws, and submission of matters to a vote of security holders.

What is Zoetis Inc.'s state of incorporation?

Zoetis Inc. is incorporated in Delaware.

What is the principal executive office address for Zoetis Inc.?

The address is 10 Sylvan Way, Parsippany, New Jersey 07054.

From the Filing

0001555280-24-000257.txt : 20240523 0001555280-24-000257.hdr.sgml : 20240523 20240523064355 ACCESSION NUMBER: 0001555280-24-000257 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240521 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240523 DATE AS OF CHANGE: 20240523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 24975159 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20240521.htm 8-K zts-20240521 0001555280 false 12/31 0001555280 2024-05-21 2024-05-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2024 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way, Parsippany, New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective May 21, 2024, Dr. Linda Rhodes retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2024 Annual Meeting of Shareholders (the &#82

View on Read The Filing